MA30811B1 - Compositions therapeutiques permettant d'augmenter l'effet d'une therapie aux anticorps contre le recepteur du facteur de croissance epidermique - Google Patents

Compositions therapeutiques permettant d'augmenter l'effet d'une therapie aux anticorps contre le recepteur du facteur de croissance epidermique

Info

Publication number
MA30811B1
MA30811B1 MA31815A MA31815A MA30811B1 MA 30811 B1 MA30811 B1 MA 30811B1 MA 31815 A MA31815 A MA 31815A MA 31815 A MA31815 A MA 31815A MA 30811 B1 MA30811 B1 MA 30811B1
Authority
MA
Morocco
Prior art keywords
growth factor
factor receptor
epidermal growth
increasing
therapeutic compositions
Prior art date
Application number
MA31815A
Other languages
English (en)
Inventor
Molina Luis Enrique Fernandez
Hidalgo Greta Garrido
Rodriguez Rolando Perez
Ramirez Belinda Sanchez
Gomez Audry Fernandez
Requena Alejandro Lopez
Delgado Irene Beausoleil
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40223744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30811(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of MA30811B1 publication Critical patent/MA30811B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

CETTE INVENTION CONCERNE DES COMPOSITIONS THÉRAPEUTIQUES SPÉCIFIQUES AUGMENTANT L'EFFICACITÉ DE LA THÉRAPIE AUX ANTICORPS MONOCLONAUX (ACMS) CONTRE LE RÉCEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE (EGFR, DE L'ANGLAIS 'EPIDERMAL GROWTH FACTOR RECEPTOR') ET DES INTERFÉRONS (INFS) DE TYPE I (A/ß).
MA31815A 2006-09-29 2009-04-23 Compositions therapeutiques permettant d'augmenter l'effet d'une therapie aux anticorps contre le recepteur du facteur de croissance epidermique MA30811B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060190A CU23612A1 (es) 2006-09-29 2006-09-29 Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico

Publications (1)

Publication Number Publication Date
MA30811B1 true MA30811B1 (fr) 2009-10-01

Family

ID=40223744

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31815A MA30811B1 (fr) 2006-09-29 2009-04-23 Compositions therapeutiques permettant d'augmenter l'effet d'une therapie aux anticorps contre le recepteur du facteur de croissance epidermique

Country Status (19)

Country Link
US (1) US20100047207A1 (fr)
EP (1) EP2070547B1 (fr)
KR (1) KR101482957B1 (fr)
CN (2) CN101678099A (fr)
AR (1) AR063011A1 (fr)
AU (1) AU2007302429B2 (fr)
BR (1) BRPI0717142A2 (fr)
CA (1) CA2664795C (fr)
CL (1) CL2007002797A1 (fr)
CO (1) CO6160338A2 (fr)
CR (1) CR10753A (fr)
CU (1) CU23612A1 (fr)
MA (1) MA30811B1 (fr)
MX (1) MX2009003159A (fr)
PE (1) PE20080674A1 (fr)
TN (1) TN2009000104A1 (fr)
TR (1) TR200902344T1 (fr)
UY (1) UY30616A1 (fr)
WO (1) WO2008037225A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0914209A2 (pt) * 2008-06-20 2015-11-03 Centro Inmunologia Molecular inibidor do receptor do fator de crscimento epidérmico, linha celular, composição farmacêutica, usos do inibidor e de um anticorpo e método
CN103536917B (zh) * 2013-10-30 2015-03-11 苏州丁孚靶点生物技术有限公司 干扰素在治疗肿瘤中的用途及相关的产品和方法
KR20180081482A (ko) * 2015-07-27 2018-07-16 이노씨맙 피티이 엘티디 표피성장인자 수용체(egfr)에 대한 단클론 항체를 이용한 췌장관선암으로 진단받은 환자의 치료

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
ATE179330T1 (de) * 1992-02-10 1999-05-15 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
CN1507355A (zh) * 2001-05-08 2004-06-23 Ĭ��ר�����޹�˾ 使用抗egfr抗体和抗激素剂的联合疗法
US20060134064A1 (en) * 2004-12-20 2006-06-22 David Goldstein Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions

Also Published As

Publication number Publication date
AU2007302429A1 (en) 2008-04-03
CL2007002797A1 (es) 2008-04-18
EP2070547A1 (fr) 2009-06-17
UY30616A1 (es) 2008-05-02
KR20090058566A (ko) 2009-06-09
EP2070547A4 (fr) 2011-11-02
TN2009000104A1 (en) 2010-08-19
CO6160338A2 (es) 2010-05-20
CN101678099A (zh) 2010-03-24
BRPI0717142A2 (pt) 2013-10-15
CN102940883A (zh) 2013-02-27
MX2009003159A (es) 2009-04-06
AU2007302429B2 (en) 2013-10-03
AR063011A1 (es) 2008-12-23
CR10753A (es) 2009-10-15
WO2008037225A1 (fr) 2008-04-03
US20100047207A1 (en) 2010-02-25
EP2070547B1 (fr) 2013-04-24
PE20080674A1 (es) 2008-07-23
CA2664795A1 (fr) 2008-04-03
TR200902344T1 (tr) 2009-08-21
KR101482957B1 (ko) 2015-01-15
CA2664795C (fr) 2014-06-17
CU23612A1 (es) 2010-12-08

Similar Documents

Publication Publication Date Title
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
IL244803A0 (en) Human anti-beta7 antibodies and their use
MX2009009146A (es) Metodos y objetivos para identificar compuestos para regular la infeccion por rinovirus.
TNSN07005A1 (fr) Analogues tetrapeptidiques
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
AU2012283775A8 (en) Inhibitors of Bruton's tyrosine kinase
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
BRPI0514721A (pt) uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
GEP20166454B (en) Sclerostin binding agents
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
GB2471588A (en) Therapeutic peptidomimetic macrocycles
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
ATE461220T1 (de) Anti-egfr-antikörper
TW200626068A (en) Active compounds for seed treatment
WO2006029219A3 (fr) Anticorps monoclonaux humains anti-ctla4 dans le traitement du cancer
WO2008112003A3 (fr) Agents liants cibles diriges contre pdgfr-alpha et utilisations associees
WO2006071952A3 (fr) Compositions et procedes pour ameliorer la fonction renale
MA33470B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone
MX360147B (es) Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos.
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.